Generic Drugs Market to See 11.02% Cagr Globally by 2018, Says a Research Report Available at Reports and Intelligence

Submitted by: Submitted by

Views: 33

Words: 416

Pages: 2

Category: Science and Technology

Date Submitted: 02/08/2015 11:00 PM

Report This Essay

Reports and Intelligence adds a report titled “Global Generic Drugs Market 2014-2018.” The report states that the global generic drugs market is expected to register a CAGR of 11.02% during the forecast period i.e. 2013-2018.

The increasing number of patent expiration is the major factor driving the growth of the global generic drugs market. The global market has also been witnessing a growing number of acquisition and mergers between the companies operating in the generic drugs market. However, the market still projects a stiff competitive landscape, which hampers the growth and affects the new entries in the global generic drugs market.

The report on the global generic drugs market consists of inputs from the industry experts, which would help the readers to evaluate the latest market trends and various other factors influencing the growth of the global generic drugs market.

Browse detailed report at: http://www.reportsandintelligence.com/global-generic-drugs-2014-2018-market

The study covers a wide range of geographical regions from all across the globe such as APAC, America and EMEA and provide detail analysis of the competitive landscape and growth prospects of the global generic drugs market.

Companies profiled in the report are Actavis plc, Mylan Inc., Novartis International AG (Sandoz), STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., 3SBio Inc., Amgen Inc., Apotex Inc., AstraZeneca plc, Aurobindo Pharma Ltd., Baxter International Inc., Berlin-Chemie AG, Biocon Ltd., Biogen Idec Inc., Boehringer Ingelheim GmbH, Celltrion Inc., Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Ltd., Gedeon Richter plc, GlaxoSmithKline plc, Hospira Inc., Impax Laboratories Inc., Intas Pharmaceuticals Ltd., Lupin Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corp., Par Pharmaceutical Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Roche Holding AG, Sanofi S.A., Wockhardt Ltd., and...